Kratom is being sold like a simple plant, but the way it’s packaged, concentrated, and marketed in 2026 can turn it into something much closer to an opioid problem hiding in plain sight. We’re taking you through a practical, clinician-friendly update drawn from a talk I gave to local therapists and drug and alcohol counselors, especially as the political and regulatory landscape shifts and bans and enforcement efforts expand in places like California.

We break down what kratom is (Mitragyna speciosa), why it can feel stimulating at low doses, and why higher doses bring opioid-receptor effects that can lead to tolerance, dependence, and withdrawal. We also cover what kratom overdose can look like, why mixing kratom with fentanyl, alcohol, or THC raises risk, and why naloxone still belongs in the conversation even when the data is often limited to case reports.

Then we get real about how people actually encounter kratom today: smoke shop “strain” menus, euphoric promises, and an online retail experience that’s faster and easier than getting medical care. The most important update is potency. Extracts are changing the game, and 7-hydroxymitragynine (7-OH) may be sold under the kratom label while acting like a far more powerful opioid. Finally, we lay out treatment pathways we use in addiction medicine, including comfort meds, tapering, Suboxone or methadone, and long-acting injectable buprenorphine (Sublocade/Brixadi) that can help some people step down without a brutal withdrawal.

If this helped you understand kratom, share it with a colleague or a friend, subscribe for more practical addiction medicine, and leave a review so more people can find the show.

To contact Dr. Grover: [email protected]

To see the podcast's ranking on millionpodcasts.com: 

https://www.millionpodcasts.com/addiction-medicine-podcasts/